STOCK TITAN

Ultragenyx (RARE) grants EVP 28,895 RSUs and 49,960 options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Ultragenyx Pharmaceutical Inc. reported that EVP and Chief Legal Officer Karah Herdman Parschauer received an equity compensation package consisting of restricted stock units and stock options. She was granted 28,895 RSUs under the company’s 2023 Incentive Plan, vesting 25% on each anniversary of the grant date over four years. She was also granted a stock option for 49,960 shares of common stock at an exercise price of $24.52 per share, expiring on April 16, 2036, with 25% vesting after one year and the remainder vesting monthly thereafter. Following these grants, she directly holds 95,715 shares of common stock, including shares underlying previously reported RSUs that remain subject to vesting conditions.

Positive

  • None.

Negative

  • None.
Insider Parschauer Karah Herdman
Role EVP and Chief Legal Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 49,960 $0.00 --
Grant/Award Common Stock 28,895 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 49,960 shares (Direct, null); Common Stock — 95,715 shares (Direct, null)
Footnotes (1)
  1. Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
RSU grant 28,895 RSUs Granted under 2023 Incentive Plan with 4-year annual vesting
Stock option grant 49,960 options Right to buy common stock, granted April 16, 2026
Option exercise price $24.52 per share Conversion or exercise price for 49,960-share option
Option expiration April 16, 2036 Expiration date of stock option grant
Shares held after awards 95,715 shares Total common stock directly held after RSU and option grants
RSU vesting schedule 25% per year RSUs vest 1/4 on each anniversary over four years
Option initial vesting 25% after one year 1/4 of option shares vest on first anniversary of grant
Restricted Stock Units ("RSUs") financial
"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2023 Incentive Plan financial
"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with underlying security title Common Stock."
vesting conditions financial
"which are subject to certain vesting conditions."
Vesting conditions are the rules that determine when someone earning company stock or stock options actually gains the right to keep or sell them, typically based on staying with the company for a set time or meeting performance targets. Think of it like keys that unlock gradually — some unlock by calendar date, others only after agreed milestones. Investors care because vesting shapes management incentives, the timing of share sales, and the number of shares that can enter the market, which can affect a company's valuation and ownership mix.
Option Anniversary Date financial
"On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest;"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Parschauer Karah Herdman

(Last)(First)(Middle)
C/O ULTRAGENYX PHARMACEUTICAL INC.
60 LEVERONI COURT

(Street)
NOVATO CALIFORNIA 94949

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Ultragenyx Pharmaceutical Inc. [ RARE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP and Chief Legal Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/16/2026A28,895(1)A$095,715(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$24.5204/16/2026A49,960 (3)04/16/2036Common Stock49,960$049,960D
Explanation of Responses:
1. Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
2. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
3. On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
/s/ Karah Parschauer04/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Ultragenyx (RARE) grant to Karah Herdman Parschauer?

Ultragenyx granted Karah Herdman Parschauer 28,895 restricted stock units and a stock option for 49,960 shares. These awards are part of her compensation and provide future share ownership subject to time-based vesting schedules and an exercise price of $24.52 for the option.

How do the new RSUs for Ultragenyx (RARE) EVP vest over time?

The 28,895 RSUs vest in four equal annual installments, with 25% of the underlying shares vesting on each anniversary of the grant date. This structure encourages long-term retention by tying actual share delivery to continued service over a four-year period.

What are the key terms of the new stock option granted by Ultragenyx (RARE)?

The new option covers 49,960 shares of common stock at a $24.52 exercise price and expires on April 16, 2036. One-quarter of the shares vest on the first anniversary of the grant, with the remaining shares vesting in equal monthly installments thereafter.

How many Ultragenyx (RARE) shares does Karah Herdman Parschauer hold after these awards?

After these awards, she directly holds 95,715 shares of Ultragenyx common stock. This total includes shares underlying previously reported RSUs that are still subject to vesting conditions, reflecting both current ownership and unvested equity compensation.

Are the Ultragenyx (RARE) awards to Karah Herdman Parschauer open-market purchases?

No. The Form 4 shows the awards as grants under the company’s 2023 Incentive Plan, with a transaction code indicating grant or award. The RSUs and stock options were issued at no cash cost per share on the grant date, not bought in the open market.